van den Buuse Maarten, Gogos Andrea
Behavioral Neuroscience Laboratory, The Mental Health Research Institute of Victoria, 155 Oak Street, Parkville, Victoria 3052, Australia.
J Pharmacol Exp Ther. 2007 Mar;320(3):1224-36. doi: 10.1124/jpet.106.113084. Epub 2006 Dec 28.
Serotonin-1A (5-HT(1A)) receptors have been implicated in the symptoms of schizophrenia. However, there is limited in vivo evidence for an interaction of antipsychotic drugs with 5-HT(1A) receptor-mediated behavioral effects. We therefore investigated in rats the action of several antipsychotic drugs on prepulse inhibition (PPI), a measure of sensorimotor gating that is deficient in schizophrenia. Disruption of PPI at the 100-ms interstimulus interval (ISI), but not the 30-ms ISI, was induced by treatment with 0.5 mg/kg 8-hydroxy-di-propylaminotetralin (8-OH-DPAT), the 5-HT(1A) receptor agonist. In rats pretreated with 0.25 mg/kg haloperidol (4-[-4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro butyrophenone) or raclopride [3,5-dichloro-N-(1-ethylpyrrolidin-2-ylmethyl)-2-hydroxy-6-methoxybenzamide tartrate], the disruption of PPI was no longer significant. Of the atypical antipsychotic drugs clozapine (8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine), olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine), risperidone [3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl) piperidino] ethyl-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one)], amisulpride (4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-o-anisamide), and aripiprazole (7-[4-[-4[-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyrilor 7-[4-[4-(2,3-dichlorophenyl) piperazin-1-yl]butoxy]-1,2,3,4,-tetrahydroquinolin-2-one), only aripiprazole significantly reduced the effect of 8-OH-DPAT on PPI. This effect was mimicked by pretreatment with the 5-HT(1A) receptor partial agonist, buspirone [N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride]. On the other hand, some of the antipsychotic drugs and other pretreatments showed complex, prepulse-dependent effects on their own. These data show little in vivo interaction of several atypical antipsychotic drugs with the disruption of PPI mediated by 5-HT(1A) receptor stimulation. The action of haloperidol and raclopride suggests a major involvement of dopamine D(2) receptors in this effect, possibly downstream from the initial serotonergic stimulation. The action of aripiprazole could be mediated by its partial agonist properties at 5-HT(1A) receptors or its dopamine D(2)-blocking properties.
5-羟色胺-1A(5-HT(1A))受体与精神分裂症的症状有关。然而,抗精神病药物与5-HT(1A)受体介导的行为效应之间相互作用的体内证据有限。因此,我们在大鼠中研究了几种抗精神病药物对前脉冲抑制(PPI)的作用,PPI是一种感觉运动门控指标,在精神分裂症中存在缺陷。用5-HT(1A)受体激动剂0.5 mg/kg 8-羟基-二丙基氨基四氢萘(8-OH-DPAT)处理可诱导100毫秒刺激间隔(ISI)时的PPI破坏,但30毫秒ISI时则不会。在用0.25 mg/kg氟哌啶醇(4-[-4-(对氯苯基)-4-羟基哌啶基]-4'-氟丁酰苯)或雷氯必利[3,5-二氯-N-(1-乙基吡咯烷-2-基甲基)-2-羟基-6-甲氧基苯甲酰胺酒石酸盐]预处理的大鼠中,PPI的破坏不再显著。在非典型抗精神病药物氯氮平(8-氯-11-(4-甲基-1-哌嗪基)-5H-二苯并[b,e][1,4]-二氮杂卓)、奥氮平(2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩并[2,3-b][1,5]苯并二氮杂卓)、利培酮[3-[2-[-4-(6-氟-1,2-苯并异恶唑-3-基)哌啶基]乙基-6,7,8,9-四氢-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮]、氨磺必利(4-氨基-N-[(1-乙基-2-吡咯烷基)甲基]-5-(乙磺酰基)-邻茴香酰胺)和阿立哌唑(7-[4-[-4[-(2,3-二氯苯基)-1-哌嗪基]丁氧基]-3,4-二氢咔唑醇或7-[4-[4-(2,3-二氯苯基)哌嗪-1-基]丁氧基]-1,2,3,4,-四氢喹啉-2-酮)中,只有阿立哌唑能显著降低8-OH-DPAT对PPI的作用。5-HT(1A)受体部分激动剂丁螺环酮[N-[4-[4-(2-嘧啶基)-1-哌嗪基]丁基]-8-氮杂螺[4.5]癸烷-7,9-二酮盐酸盐]预处理可模拟这种效应。另一方面,一些抗精神病药物和其他预处理自身显示出复杂的、依赖前脉冲的效应。这些数据表明几种非典型抗精神病药物与5-HT(1A)受体刺激介导的PPI破坏之间在体内几乎没有相互作用。氟哌啶醇和雷氯必利的作用表明多巴胺D(2)受体在这种效应中起主要作用,可能在最初的5-羟色胺能刺激的下游。阿立哌唑的作用可能由其在5-HT(1A)受体上的部分激动剂特性或其多巴胺D(2)阻断特性介导。